| Understanding and managing methotrexate nephrotoxicity BC Widemann, PC Adamson The oncologist 11 (6), 694-703, 2006 | 873 | 2006 |
| Activity of selumetinib in neurofibromatosis type 1–related plexiform neurofibromas E Dombi, A Baldwin, LJ Marcus, MJ Fisher, B Weiss, AR Kim, P Whitcomb, ... New England Journal of Medicine 375 (26), 2550-2560, 2016 | 643 | 2016 |
| Selumetinib in children with inoperable plexiform neurofibromas AM Gross, PL Wolters, E Dombi, A Baldwin, P Whitcomb, MJ Fisher, ... New England Journal of Medicine 382 (15), 1430-1442, 2020 | 520 | 2020 |
| Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ... Cancer cell 31 (6), 833-843. e5, 2017 | 472 | 2017 |
| Low-intensity therapy in adults with Burkitt's lymphoma K Dunleavy, S Pittaluga, M Shovlin, SM Steinberg, D Cole, C Grant, ... New England Journal of Medicine 369 (20), 1915-1925, 2013 | 398 | 2013 |
| High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome BC Widemann, FM Balis, B Kempf‐Bielack, S Bielack, CB Pratt, S Ferrari, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 389 | 2004 |
| MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors WJ Jessen, SJ Miller, E Jousma, J Wu, TA Rizvi, ME Brundage, D Eaves, ... The Journal of clinical investigation 123 (1), 340-347, 2013 | 357 | 2013 |
| Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a … MM Miettinen, CR Antonescu, CDM Fletcher, A Kim, AJ Lazar, ... Human pathology 67, 1-10, 2017 | 349 | 2017 |
| Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1 VF Mautner, FA Asuagbor, E Dombi, C Fünsterer, L Kluwe, R Wenzel, ... Neuro-oncology 10 (4), 593-598, 2008 | 256 | 2008 |
| Sustained response and prevention of damage progression in patients with neonatal‐onset multisystem inflammatory disease treated with anakinra: a cohort study to determine … CH Sibley, N Plass, J Snow, EA Wiggs, CC Brewer, KA King, C Zalewski, ... Arthritis & Rheumatism 64 (7), 2375-2386, 2012 | 237 | 2012 |
| NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight E Dombi, J Solomon, AJ Gillespie, E Fox, FM Balis, N Patronas, BR Korf, ... Neurology 68 (9), 643-647, 2007 | 210 | 2007 |
| Consensus guideline for use of glucarpidase in patients with high‐dose methotrexate induced acute kidney injury and delayed methotrexate clearance LB Ramsey, FM Balis, MM O'Brien, K Schmiegelow, JL Pauley, A Bleyer, ... The oncologist 23 (1), 52-61, 2018 | 195 | 2018 |
| Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome BC Widemann, FM Balis, AR Kim, M Boron, N Jayaprakash, A Shalabi, ... Journal of clinical oncology 28 (25), 3979-3986, 2010 | 194 | 2010 |
| Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma E Fox, BC Widemann, MK Chuk, L Marcus, A Aikin, PO Whitcomb, ... Clinical Cancer Research 19 (15), 4239-4248, 2013 | 180 | 2013 |
| High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease J Rübo, K Albrecht, P Lasch, E Laufkötter, J Leititis, D Marsan, ... The Journal of pediatrics 121 (1), 93-97, 1992 | 173 | 1992 |
| Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform … BC Widemann, WL Salzer, RJ Arceci, SM Blaney, E Fox, D End, ... Journal of clinical oncology 24 (3), 507-516, 2006 | 169 | 2006 |
| Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. BC Widemann, FM Balis, RF Murphy, JM Sorensen, MJ Montello, ... Journal of clinical oncology 15 (5), 2125-2134, 1997 | 168 | 1997 |
| Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group … JP Lagmay, MD Krailo, H Dang, AR Kim, DS Hawkins, O Beaty III, ... Journal of Clinical Oncology 34 (25), 3031-3038, 2016 | 165 | 2016 |
| Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum VER Parker, KM Keppler-Noreuil, L Faivre, M Luu, NL Oden, L De Silva, ... Genetics in Medicine 21 (5), 1189-1198, 2019 | 157 | 2019 |
| Sirolimus for progressive neurofibromatosis type 1–associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study B Weiss, BC Widemann, P Wolters, E Dombi, A Vinks, A Cantor, ... Neuro-oncology 17 (4), 596-603, 2015 | 156 | 2015 |
